GNOM
Reasons to Consider GNOM
High Growth Potential
Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1
Structural Tailwinds
Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 37% compound annual growth rate from 2024-2030.2
Targeted Exposure
GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.
1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, n.d., Technology Overviews of: Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy, and Genome Editing, all accessed 6 Jun 2025.
| Key Information |
| ETF Summary |
ETF Objective
| Trading Details |
| Distributions |
ETF Prices
| NAV | Daily Change | |||
| Market Price | Daily Change |
Performance History
| Fund NAV | Market Price | Index | |
|---|---|---|---|
| Options Details |
Top Holdings
| Net Assets (%) | Ticker | Name | SEDOL | Shares Held | Market Value |
|---|---|---|---|---|---|
| Exposure |
| ETF Characteristics |
| ETF Risk Stats |
ETF Research
ETF Documents
Prospectus & Regulatory Information
* The financial statements include the Fund’s disclosures required by Items 7 through 11 of Form N-CSR, which includes the financial statements, financial highlights, and other important information when applicable.
** The financial statements include the Fund’s disclosures required by Items 7 through 11 of Form N-CSR, which includes the financial statements, financial highlights, and other important information when applicable.